Chris Sotirelis, PhD, is a patient advocate engaged at national and international level for many years.
As an EMA Expert, he has been directly involved in developments of regulatory policy and in the latest trends for emerging drug development as it increasingly shifts away from the traditional models and more towards the individual patient.
In his capacity as patient expert and observer in the EMA CAT he has focused on the new paradigms for ATMPs of Adaptive Pathways and PRIME. His advocacy is aimed at optimising the development of medicinal products using accelerated clinical development timelines for Marketing Authorisation to be always based on truly patient centric models.
He has been involved in many HTA Parallel Scientific Advice sessions at EMA as well as in others areas of access and reimbursement policy. He regularly participates in HTA related and European payer led projects with MEDEV, EUnetHTA and the Mechanism of Coordinated Access (MOCA).